Edgeline Holdings, Inc. (ELHI.OB) Agrees to Terms for an Exclusive Worldwide Right to Option Patents Covering the Composition and Use of Genistein Analogs for Cancer Treatment
Edgeline Holdings, Inc. (ELHI.OB), a biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies, recently announced that the company has agreed to terms for an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment.
This technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents. Due to the widespread success of antimicrotubule therapies in curative and palliative cancer treatment, the microtubule is one of the best cancer targets identified to date.
According to a report by the research firm Frost & Sullivan, the cancer-therapies market is estimated to be approximately $32 billion and is expected to reach nearly $70 billion by 2010. Edgeline Holdings is well positioned to meet the significant need for more effective cancer-fighting therapies that offer reduced side effects. In addition, the company recently announced it has obtained an exclusive option agreement with The University of Texas M.D. Anderson Cancer Center. This agreement will provide the company with rights to negotiate a license for five technologies relating to the treatment of various cancers over a nine-month period.
Let us hear your thoughts below: